1-10 of 10
Elad Sharon, MD MPH
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)

Amer M. Zeidan, MBBS, MHS, Victoria Wang, Jerald P. Radich, MD, Jan Philipp Bewersdorf, MD, Vijaya R. Bhatt, MD, Elad Sharon, MD MPH, Steven D. Gore, MD, Selina M. Luger, MD FRCPC, Mark Litzow, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1.
https://doi.org/10.1182/blood-2020-137734
Published: 2020
Journal Articles

Blast MRD AML-2: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MDR) in Acute Myeloid Leukemia (AML) 2- a Randomized Phase 2 Study of the Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine As First Line Therapy in Older Patients with AML Who Are Ineligible or Who Refuse Intensive Chemotherapy

Amer M. Zeidan, MBBS, MHS, Prajwal Boddu, MD, Brent L Wood, MD PhD, Daniel Zelterman, Richard F. Little, MDMPH, S. Percy Ivy, MD, Anne Caldwell, Beatriz Sanchez-Espiridion, Gheath Alatrash, Elad Sharon, MD MPH, Jerald P. Radich, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-139752
Published: 2020
Journal Articles

Blast MRD AML-1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia (AML) 1- an Investigator-Initiated, CTEP-Sponsored, Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy (IC) As Frontline Therapy in Patients with Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Prajwal C Boddu, MBBS, Brent L Wood, MD PhD, Daniel Zelterman, Richard F. Little, MDMPH, S. Percy Ivy, MD, Anne Caldwell, Beatriz Sanchez-Espiridion, Gheath Alatrash, Elad Sharon, MD MPH, Jerald P. Radich, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 15.
https://doi.org/10.1182/blood-2020-139668
Published: 2020
Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, MD, Lingyun Ji, PhD, Xinxin Xu, MS, Meenakshi Devidas, PhD, Laura Hogan, MD, Michael J. Borowitz, MD PhD, Elizabeth A. Raetz, MD, Gerhard Zugmaier, Elad Sharon, MD MPH, Lia Gore, MD, James A. Whitlock, MD, Michael A. Pulsipher, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD
Journal: Blood
Blood (2019) 134 (Supplement_2): LBA-1.
https://doi.org/10.1182/blood-2019-132435
Published: 2019
Journal Articles

Safety and Efficacy of Brentuximab Vedotin in Combination with AVD in Stage II-IV HIV-Associated Classical Hodgkin Lymphoma: Results of the Phase 2 Study, AMC 085

Paul G. Rubinstein, MD, Page C. Moore, PhD, Milan Bimali, PhD, Amy Chadburn, MD, Ethel Cesarman, MD PhD, Michelle Rudek, PharmD, PhD, Lee Ratner, MD PhD, Richard F. Ambinder, MD, David H. Henry, MD, Stefan K. Barta, MD MRCP, MS, Herve Ghesquieres, MD PhD, Paul Coppo, MD PhD, Pierre Delobel, MD, Francois Boue, MD PhD, Lionel Galicier, MD, Juan Carlos Ramos, MD BS, Erin G. Reid, MD MS, Elad Sharon, MD MPH, Nicolas Mounier, MD, Caroline Besson, MD PhD, Ariela Noy, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 130.
https://doi.org/10.1182/blood-2019-126787
Published: 2019
Journal Articles

The DIAL Study (Dual Immunomodulation in Aggressive Lymphoma): A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas (NCI 10089 / NCT03038672)

Jose C Villasboas, MD, Craig B. Reeder, MD, Han W. Tun, MD, Nancy L Bartlett, MD, Elad Sharon, MD MPH, Betsy Laplant, MS, Alex A Adjei, MD PhD, Justin Kline, MD, Francisco J. Hernandez-Ilizaliturri, MD, Farrukh T. Awan, MD, Sumana Devata, MD, Aleksandr Lazaryan, MDPhDMPH, Lawrence E Morris, MD, Stephen M Ansell, MD PhD, Catherine Diefenbach, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1591.
https://doi.org/10.1182/blood-2019-130449
Published: 2019
Journal Articles

Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study

Jonathan Webster, MD, Marlise R. Luskin, MD, Gabrielle T. Prince, MD, Amy E. DeZern, MD, Daniel J. DeAngelo, MD, Mark J. Levis, MD, Amanda Blackford, Elad Sharon, MD MPH, Howard Streicher, MD, Leo Luznik, MD, Ivana Gojo, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 557.
https://doi.org/10.1182/blood-2018-99-111845
Published: 2018
Journal Articles

Durable Responses with Pembrolizumab in Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Final Results from a Phase 2 Multicenter Study

Michael S Khodadoust, MD PhD, Alain Rook, MD, Pierluigi Porcu, MD, Francine M. Foss, MD, Alison J. Moskowitz, MD, Andrei R. Shustov, MD, Satish Shanbhag, MD, Lubomir Sokol, MD PhD, Steven P Fling, PhD, Shufeng Li, MS, Asa Davis, PhD, Sophia Fong, BS, Jinah Kim, MD PhD, Yi Yang, Jennifer H Yearley, PhD DVM, Priyanka B Subrahmanyam, PhD, Holden T. Maecker, PhD, Yelena Budovskaya, PhD, Biswajit Das, PhD, Rajesh Patidar, PhD, Vivekananda Datta, MD PhD, Chris Karlovich, PhD, Steven M. Horwitz, MD, Elad Sharon, MD MPH, Holbrook Kohrt, MD PhD, Martin A Cheever, MD, Youn H. Kim, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2896.
https://doi.org/10.1182/blood-2018-99-117244
Published: 2018
Journal Articles

Pembrolizumab for Treatment of Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome: Clinical Efficacy in a Citn Multicenter Phase 2 Study

Michael Khodadoust, MD PhD, Alain H. Rook, MD, Pierluigi Porcu, MD, Francine M. Foss, MD, Alison J. Moskowitz, MD, Andrei R Shustov, MD, Satish Shanbhag, MBBS, MPH, Lubomir Sokol, MD PhD, Richard Shine, PharmD, Steven P Fling, PhD, Shufeng Li, MS, Ziba Rabhar, Jinah Kim, MD PhD, Yi Yang, Jennifer Yearley, DVM, PhD, Elliot Keith Chartash, MD, Steven M. Townson, PhD, Priyanka B Subrahmanyam, PhD, Holden Maecker, PhD, Ash A. Alizadeh, MD PhD, Julia Dai, MD, Steven M Horwitz, MD, Elad Sharon, MD MPH, Holbrook Kohrt, MD, Martin A Cheever, MD, Youn Kim, MD
Journal: Blood
Blood (2016) 128 (22): 181.
https://doi.org/10.1182/blood.V128.22.181.181
Published: 2016
Journal Articles

AMC-085: A Pilot Trial of AVD and Brentuximab Vedotin in the Upfront Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma. A Trial of the AIDS Malignancy Consortium

Paul G. Rubinstein, MD, Page Moore, PhD, David H. Henry, MD, Lee Ratner, MD PhD, Elad Sharon, MD MPH, Ariela Noy, MD
Journal: Blood
Blood (2015) 126 (23): 1526.
https://doi.org/10.1182/blood.V126.23.1526.1526
Published: 2015